Literature DB >> 7307855

Properties and hepatic metabolism of non-transferrin-bound iron.

R G Batey, S Shamir, J Wilms.   

Abstract

These experiments have examined the physical properties and the hepatic uptake of non-transferrin-bound iron, a fraction found in the serum of untreated primary hemochromatosis patients. Ultrafiltration, polyacrylamide gel electrophoresis, and TLC have demonstrated the non-transferrin-bound iron complex to have a molecular weight less than 1000 and to be distinct from free iron and amino acid iron complexes. Hepatic iron uptake from serum containing non-transferrin-bound iron was significantly higher than from the same serum sample from which the abnormal iron had been removed. Non-transferrin-bound iron entering the liver was localized to the lysosomal fraction in the first hour and was subsequently incompletely incorporated into ferritin. The results demonstrated an abnormal uptake of this iron fraction by the liver and suggest that the abnormal serum fraction may contribute to tissue damage by entering the lysosomes.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7307855     DOI: 10.1007/bf01295972

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  15 in total

1.  FERROKINETICS: A STUDY OF TRANSPORT IRON IN PLASMA.

Authors:  F HOSAIN; C A FINCH
Journal:  J Lab Clin Med       Date:  1964-12

2.  Uptake of transferrin-bound iron by rat cells in tissue culture.

Authors:  M R Beamish; L Keay; T Okigaki; E B Brown
Journal:  Br J Haematol       Date:  1975-12       Impact factor: 6.998

3.  Transferrin and iron uptake by the liver in the rat.

Authors:  M E Gardiner; E H Morgan
Journal:  Aust J Exp Biol Med Sci       Date:  1974-10

4.  Transient hepatic deposition of iron im primary hemochromatosis with iron deficiency following venesection.

Authors:  M Pollycove; R A Fawwaz; H S Winchell
Journal:  J Nucl Med       Date:  1971-01       Impact factor: 10.057

5.  State of iron(3) in normal human serum: low molecular weight and protein ligands besides transferrin.

Authors:  B Sarkar
Journal:  Can J Biochem       Date:  1970-12

6.  Organelle pathology in primary and secondary haemochromatosis with special reference to lysosomal changes.

Authors:  C A Seymour; T J Peters
Journal:  Br J Haematol       Date:  1978-10       Impact factor: 6.998

7.  A non-transferrin-bound serum iron in idiopathic hemochromatosis.

Authors:  R G Batey; P Lai Chung Fong; S Shamir; S Sherlock
Journal:  Dig Dis Sci       Date:  1980-05       Impact factor: 3.199

8.  The mechanism of hepatic iron uptake from native and denatured transferrin and its subcellular metabolism in the liver cell.

Authors:  J P Milsom; R G Batey
Journal:  Biochem J       Date:  1979-07-15       Impact factor: 3.857

9.  Hepatic iron clearance from serum in treated hemochromatosis.

Authors:  R G Batey; J E Pettit; A W Nicholas; S Sherlock; A V Hoffbrand
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

10.  Effect of iron stores and hysterectomy on iron absorption and distribution in pregnant mice.

Authors:  R Batey; N Gallagher
Journal:  Am J Physiol       Date:  1977-01
View more
  4 in total

1.  Regulation of intestinal non-haem iron absorption.

Authors:  M Lombard; E Chua; P O'Toole
Journal:  Gut       Date:  1997-04       Impact factor: 23.059

2.  Accumulation of iron by primary rat hepatocytes in long-term culture: changes in nuclear shape mediated by non-transferrin-bound forms of iron.

Authors:  E E Cable; J R Connor; H C Isom
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

3.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

Authors:  P Brissot; T L Wright; W L Ma; R A Weisiger
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

Review 4.  Liver iron transport.

Authors:  Ross-M Graham; Anita-C-G Chua; Carly-E Herbison; John-K Olynyk; Debbie Trinder
Journal:  World J Gastroenterol       Date:  2007-09-21       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.